The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Screening of TROP2, Nectin-4, and HER2 in osteosarcomas: In pursuit of a target.
 
Anna Boulouta
No Relationships to Disclose
 
Panagiota Economopoulou
No Relationships to Disclose
 
Ioannis Kotsantis
No Relationships to Disclose
 
Panagiotis Vlachostergios
No Relationships to Disclose
 
Myrto Moutafi
No Relationships to Disclose
 
Maria Kyrkasiadou
No Relationships to Disclose
 
Maria Anastasiou
No Relationships to Disclose
 
Anastasios Pantazopoulos
No Relationships to Disclose
 
Pinelopi Korkolopoulou
No Relationships to Disclose
 
Eleftheria Lakiotaki
No Relationships to Disclose
 
Georgios Agrogiannis
No Relationships to Disclose
 
Dionysis Papachristou
No Relationships to Disclose
 
Panagiotis Papagelopoulos
No Relationships to Disclose
 
Vasileios Kontogeorgakos
No Relationships to Disclose
 
Amanda Psyrri
Honoraria - Astrazeneca; Bayer; BMS; Genesis Pharmaceuticals; GlaxoSmithKline; Merck Serono; merus; MSD Oncology; Pfizer; Roche; seagen
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; eTheRNA immunotherapies; GlaxoSmithKline; Merus NV; MSD Oncology; Pfizer; Seagen
Research Funding - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Demo Pharmaceutical; Kura Oncology; Pfizer; Pharmathen; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Ipsen; MSD Oncology; Roche
(OPTIONAL) Uncompensated Relationships - AstraZeneca; AstraZeneca
 
Anastasios Kyriazoglou
Honoraria - BMS GmbH & Co. KG; Genesis Pharma; Ipsen; MSD